
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts

Recommendation for Teplizumab Type 1 Diabetes Routine Use
Teplizumab for Type 1 Diabetes now has a clear route to routine NHS use after NICE recommended the therapy for delaying progression from stage 2 to stage 3 disease in people aged 8 and older. The decision, dependent on a confidential commercial discount, offers families more time before insulin d...

Lingjian Morphology Diagnostics Transforming Clinical Laboratory Practices
Lingjian Morphology Diagnostics transforms microscopic analysis in clinical laboratories by uniting image interpretation, cell classification, morphological description, target localization, and natural language interaction within a single vision-language architecture. Developed to overcome pract...

Joint Scientific Consultation EU Strategies for Medical Device Companies
The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their developme...